切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2018, Vol. 07 ›› Issue (01) : 1 -3. doi: 10.3877/cma.j.issn.2095-3216.2018.01.001

所属专题: 文献

述评

中药的用药安全及在肾病中的合理应用
李平1,(), 陈姣伊1, 李丹丹1   
  1. 1. 100029 北京,中日友好医院,免疫炎性疾病北京市重点实验室
  • 收稿日期:2017-11-29 出版日期:2018-02-28
  • 通信作者: 李平
  • 基金资助:
    国家自然基金重点国际(地区)合作研究重点项目(81620108031)

The safety of Chinese medicine and its rational application in nephropathy

Ping Li1,(), Jiaoyi Chen1, Dandan Li1   

  1. 1. China-Japan Friendship Hospital, Beijing Key Laboratory of Immunoinflammatory Diseases, Beijing 100029, China
  • Received:2017-11-29 Published:2018-02-28
  • Corresponding author: Ping Li
  • About author:
    Corresponding author: Li Ping, Email:
引用本文:

李平, 陈姣伊, 李丹丹. 中药的用药安全及在肾病中的合理应用[J/OL]. 中华肾病研究电子杂志, 2018, 07(01): 1-3.

Ping Li, Jiaoyi Chen, Dandan Li. The safety of Chinese medicine and its rational application in nephropathy[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(01): 1-3.

中医药是中华民族的宝贵财富,在治疗一些复杂疑难疾病中起了重要的作用,近年来已逐渐在世界范围内被普遍应用于预防和治疗疾病。然而由于中草药成分复杂,临床用药的安全问题屡见不鲜,因此在中药的使用中我们需要十分关注药物的不良反应。大多数药物均经肾脏排泄,药物引起的肾损害也是临床医生关注的热点问题。为确保中药在肾脏病中的合理应用,我们应当注意在中医理论指导下合理用药,并依照患者的体质和基础病个体化用药,同时合理选择药物来源及加工炮制方法,严格掌握用药剂量与疗程。

Chinese medicine is the precious wealth of our country, plays an important role in the treatment of many complicated diseases, and is commonly used worldwide for preventive and therapeutic purposes during recent decades. However, the safety of herbal products has been widely questioned, especially their potential nephrotoxicity. In the use of Chinese medicine, we still need to attach great attention to its adverse reactions. Since most drugs are excreted by the kidney, drug-induced renal damage is always a deeply-concerned issue among clinicians. To ensure rational application of Chinese medicine in kidney diseases, we should make prescriptions under the guidance of traditional Chinese medicine (TCM) theory, provide individualized treatment options in accordance with patients′ constitution and basic diseases, select drug sources and processing technology reasonably, and strictly control the dosage and course of therapy.

[1]
Hong CD. Complementary and alternative medicine in Korea: current status and future prospects [J]. J Altern Complement Med, 2001, 7(Suppl 1): 33-40.
[2]
Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine in Taiwan [J]. BMC Health Serv Res, 2007, 7(1): 1-11.
[3]
Eisenberg D, Davis R, Ettner S. Trends in alternative medicine use in the United States [J]. JAMA, 1997, 280(6): 370-371.
[4]
Yamashita H, Tsukayama H, Sugishita C. Popularity of complementary and alternative medicine in Japan: a telephone survey [J]. Complement Ther Med, 2002, 10(2): 84-93.
[5]
Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem [J]. Kidney Int, 2008, 74(2): 158-169.
[6]
Ingsathit A, Thakkinstian A, Chaiprasert A, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study [J]. Nephrol Dial Transplant, 2010, 25(5): 1567-1575.
[7]
冯雪,方赛男,高雨鑫,等. 中药肾毒性国内外研究现状[J]. 中国中药杂志,2018, 43(3): 417-424.
[8]
Lai MN, Lai JN, Chen PC, et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study [J]. Am J Kidney Dis, 2010, 55(3): 507-518.
[9]
关建红,翁维良. 对中药"毒性"与毒性分级的思考[J]. 中国中药杂志,2008, 33(4): 485-487.
[10]
Loh AH, Cohen AH. Drug-induced kidney disease-pathology and current concepts [J]. Ann Acad Med Singapore, 2009, 38(3): 240-250.
[11]
Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney [J]. Kidney Int, 2000, 58(3): 944-958.
[12]
张松波,周宏灏. 药物代谢性别差异及与核受体的关系[J]. 中国药理学通报,2007, 23(3): 292-294.
[13]
Schlender JF, Vozmediano V, Golden AG, et al. Current strategies to streamline pharmacotherapy for older adults [J]. Eur J Pharm Sci, 2017, 111: 432-442.
[14]
时琳,薛颖. 含毒性成分中成药的应用探讨[J]. 中成药,2015, 37(7): 1626-1629.
[15]
阳长明. 乌头碱类成分中药制剂质量控制探讨[J]. 药品评价,2011, 8(10): 23-27.
[16]
李娆娆,张志杰,王祝举,等. 近60年中药毒副作用及不良反应文献分析[J]. 中国实验方剂学杂志,2010, 16(15): 213-216,221.
[1] 唐小清, 何萍, 杨友, 罗霞, 张菊英, 杨鑫, 余进洪. 声触诊弹性成像联合脉冲多普勒超声成像参数与早期慢性肾脏病分期的相关性及临床价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 491-499.
[2] 刘涵, 刘晓菲, 陈翰翰, 陈延君, 张雁. 妊娠期肉芽肿性乳腺炎一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(04): 253-254.
[3] 诸琴红, 夏典平, 葛芳娣, 崔大伟. 抗氧化和炎症指标在糖尿病肾病患者中的临床意义[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 307-311.
[4] 费扬, 赵晗希, 孙丽琴, 楼琴华, 胡骏程. 银杏叶提取物对糖尿病肾病患者的疗效及其对尿液外泌体miR-342-3p的干预研究[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(03): 219-224.
[5] 万周程, 钟章锋, 钟侨霖, 王景浩, 刘婷, 王华军, 郑小飞. 中药有效成分结合生物材料在骨组织工程中作用的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(04): 249-253.
[6] 史彬, 司远. 益气和络方联合缬沙坦治疗气阴两虚兼血瘀证IgA 肾病的疗效观察[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 306-312.
[7] 国文凯, 纪鹏程, 毕靖茹, 谢院生. IgA 肾病的十种治疗措施[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 327-333.
[8] 施麟宵, 洪兰兰, 阳柳, 芶碧珍, 刘畅, 吴欣. 钠-葡萄糖协同转运蛋白2 抑制剂治疗原发性膜性肾病的疗效及其对Th1/Th2 的影响[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 261-267.
[9] 孙顗淼, 张颖. 糖尿病患者急性脑梗死取栓术后发生对比剂肾病的影响因素及预测模型建立[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 188-194.
[10] 张勤灵, 王盼飞, 赵倩文. 尿β2-微球蛋白在原发性膜性肾病预后评估中的作用[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 195-200.
[11] 赵静, 张嘉欣, 高言, 谢席胜. 微小病变肾病的发病机制及治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 207-212.
[12] 孙鼎, 王滨, 陈香美, 陈意志. 热应激肾病的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(03): 170-176.
[13] 邱岭, 朱旭丽, 浦坚, 邢苗苗, 吴佳玲. 糖尿病肾病患者肠道菌群生态特点与胃肠道功能障碍的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 453-458.
[14] 石佳娜, 钱琳艳, 姬凯悦, 祁金文, 胡情, 孙佳斌. 从PVAT 白色脂肪棕色化角度探讨中药在防治动脉粥样硬化中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 853-858.
[15] 李忠清, 罗军. 尿蛋白电泳在浆细胞疾病鉴别诊断中的价值[J/OL]. 中华诊断学电子杂志, 2024, 12(04): 217-221.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?